The Department of Health and Human Services today announced an agreement with drug maker Gilead Sciences to allow U.S. hospitals to purchase up to 500,000 treatment courses of remdesivir through September, which HHS and state health departments will allocate as they did the previous 120,000 treatment courses donated by the drug maker.

Under the agreement, hospitals will pay no more than the wholesale acquisition price for the drug, or $3,200 per treatment course, which AmerisourceBergen likely will ship to them every two weeks. The investigational drug has shown encouraging results treating certain COVID-19 patients in early clinical trials. HHS said the final donated treatment courses will ship today. To make future allocations of remdesivir, HHS will be asking hospitals and health systems to submit data every two weeks. The next data collection will be July 6.

AHA members will receive a Special Bulletin with more details.

Related News Articles

Headline
Throughout the COVID-19 pandemic, Sutter Health in Northern California used the range of its system to meet the needs of patients, staff and clinicians, from…
Headline
U.S. life expectancy fell by an average of 1.5 years in 2020 to 77.3 years, primarily due to COVID-19, the Centers for Disease Control and Prevention reported…
Headline
The AHA Board of Trustees yesterday adopted a policy statement that supports hospitals and health systems that adopt mandatory COVID-19 vaccination…
Headline
The AHA, American Medical Association and American Nurses Association today released a public service announcement urging the American public to “ask questions…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective July 20. The extension…
Headline
The Department of Health and Human Services should provide projected time frames for its planned spending of COVID-19 relief funds, including the Provider…